After William Blair and H.C. Wainwright gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy reiterated a Buy rating on Celyad today. The company’s shares closed last Monday at $8.20.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 44.7% and a 57.6% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Adaptimmune Therapeutics.
Currently, the analyst consensus on Celyad is a Strong Buy with an average price target of $18.00, which is an 119.5% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Celyad’s market cap is currently $114.3M and has a P/E ratio of -3.80. The company has a Price to Book ratio of -19.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
